Get the Stockscreener App
9.95
12.35%
-1.38
Adma Biologics Inc stock is traded at $9.95, with a volume of 19.66M.
It is down -12.35% in the last 24 hours and down -36.66% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
See More
Previous Close:
$11.33
Open:
$11.45
24h Volume:
19.66M
Relative Volume:
5.84
Market Cap:
$2.36B
Revenue:
$510.17M
Net Income/Loss:
$146.93M
P/E Ratio:
16.61
EPS:
0.599
Net Cash Flow:
$27.51M
1W Performance:
-33.21%
1M Performance:
-36.66%
6M Performance:
-35.18%
1Y Performance:
-50.89%
1-Day Range:
$8.62
$11.45
1-Week Range:
$8.62
$15.22
52-Week Range:
$8.62
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
9.91 | 2.70B | 510.17M | 146.93M | 27.51M | 0.599 |
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.57 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
326.88 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
696.67 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.50 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
ADMA Biologics (ADMA) Responds to Short Report, Shares Drop 17% - GuruFocus
ADMA Biologics Responds to Negative Short Report - GuruFocus
ADMA Biologics responds to short seller report - Investing.com
ADMA Biologics Addresses Misleading Short-Seller Report - The Manila Times
New Strong Buy Stocks for March 25th - Yahoo Finance Singapore
ADMA Biologics (ADMA) Shares Drop 15% Following Short Report - GuruFocus
Assessing ADMA Biologics (ADMA) Valuation After Fresh Analyst Upgrades And Strong Buy Sentiment - Sahm
ADMA Biologics (NASDAQ:ADMA) Stock Price Down 8.7%What's Next? - MarketBeat
ADMA Stock Drops 17% After Culper Research Alleges Channel Stuffing - Stocktwits
ADMA stock drops 6% after Culper Research alleges channel stuffing - MSN
ADMA Shares Decline Amid Controversy Over Revenue Growth - GuruFocus
Adma Biologics Shares Drop After Short Report - Intellectia AI
ADMA Biologics shares plunge on short seller allegations - Investing.com
Culper Research Says We Are Short ADMA Biologics - TradingView
Adma Biologics stock hits 52-week low at 13.76 USD By Investing.com - Investing.com Australia
ADMA Biologics (NASDAQ:ADMA) Sets New 52-Week LowHere's Why - MarketBeat
Adma Biologics stock hits 52-week low at 13.76 USD - Investing.com
ADMA Biologics (ADMA) announces $200M capital return program including $125M ASR agreement - MSN
ADMA Biologics (ADMA) Announces $200M Capital Return Program Including $125M ASR Agreement - Yahoo Finance
10 Best NASDAQ Stocks Under $30 to Buy - Insider Monkey
(ADMA) Volatility Zones as Tactical Triggers - Stock Traders Daily
Tealwood Asset Management Inc. Invests $1.32 Million in ADMA Biologics Inc $ADMA - MarketBeat
Tealwood Asset Management Inc. Takes Position in ADMA Biologics Inc $ADMA - MarketBeat
Has The Pullback In ADMA Biologics (ADMA) Opened A New Valuation Opportunity? - Yahoo Finance
ADMA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ADMA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors - Yahoo Finance
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy? - Yahoo Finance
ADMA Biologics (NASDAQ:ADMA) Stock Price Down 8.1%Should You Sell? - MarketBeat
Adma Biologics (ADMA) upgraded to strong buy: Here's why - MSN
Technical Analysis: Will ADMA Biologics Inc face regulatory challenges2026 Highlights & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Adma Biologics CEO Grossman sells $318k in shares - Investing.com
ADMA Biologics (ADMA) CEO exercises options and sells 21K shares - Stock Titan
Why the market dipped but Adma Biologics (ADMA) gained today - MSN
Adma Biologics (ADMA) registers a bigger fall than the market: Important facts to note - MSN
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum - MSN
Tech Rally: Will ADMA Biologics Inc face regulatory challenges2026 Price Action Summary & Technical Pattern Alert System - baoquankhu1.vn
FDA-Approved Yield Boost For ASCENIV Might Change The Case For Investing In ADMA Biologics (ADMA) - Sahm
Zacks Industry Outlook Features Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals, and Liquidia - Bitget
Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia - The Globe and Mail
HighVista Strategies LLC Invests $1.39 Million in ADMA Biologics Inc $ADMA - MarketBeat
First Light Asset Management LLC Buys 117,137 Shares of ADMA Biologics Inc $ADMA - MarketBeat
A Look At ADMA Biologics (ADMA) Valuation After Recent Share Price Swings - Yahoo Finance
Assessing ADMA Biologics (ADMA) Valuation After Recent Share Price Pullback And Mixed Performance Signals - simplywall.st
Boothbay Fund Management LLC Makes New $11.33 Million Investment in ADMA Biologics Inc $ADMA - MarketBeat
Marathon Capital Management Has $6.84 Million Holdings in ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics Inc $ADMA Shares Bought by B Group Inc. - MarketBeat
Reassessing ADMA Biologics (ADMA) After Multi Year Surge And Recent Share Price Pullback - simplywall.st
Why the Market Dipped But Adma Biologics (ADMA) Gained Today - Yahoo Finance
WINTON GROUP Ltd Has $1.03 Million Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
Magnetar Financial LLC Makes New Investment in ADMA Biologics Inc $ADMA - MarketBeat
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adma Biologics Inc Stock (ADMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Option Exercise |
5.40 |
15,000 |
81,000 |
2,133,777 |
| Grossman Adam S | President and CEO |
Mar 16 '26 |
Sale |
15.16 |
21,000 |
318,360 |
2,112,777 |
2.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):